UT MD Anderson's New Insights at ASTRO 2026 Highlight Advances in Radiation Therapy
The 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO) has set the stage for revealing cutting-edge research in the domain of radiation therapy, spotlighting key findings from UT MD Anderson Cancer Center. Among several notable studies, four abstracts have emerged, indicating substantial potential for improving cancer treatment outcomes.
One study examined the use of stereotactic body radiotherapy (SBRT) in patients with recurrent head and neck squamous cell carcinoma. The Phase 2 SOAR-HN trial, led by Dr. Jack Phan, evaluated the safety and efficacy of SBRT compared to standard reirradiation. Results showed that patients treated with conventional radiation were more likely to experience severe (Grade 3 or higher) toxicity compared to those treated with SBRT, without compromise in survival rates. "Reirradiation for recurrent head and neck cancer is one of the more challenging areas in oncology," Phan commented, emphasizing the shorter treatment period and reduced side effects with SBRT. Dr. Liam Spurr is scheduled to present this study on September 29, 2026.
Another investigation focused on stereotactic spine radiosurgery (SSRS) and evaluated whether preventive bone cement application could mitigate fracture risk for patients undergoing SSRS. Led by Dr. Amol Ghia, the study found that bone cement did not significantly lower fracture rates, though it is generally safe. Ghia stated, "Preventive cement shouldn't be routine. A fracture can usually be addressed, whereas tumor regrowth at the treated site often cannot be." Dr. Amol Ghia will present these findings on September 30, 2026.
The efficacy of combination therapy for non-small cell lung cancer (NSCLC) was highlighted in the I-SABR Phase 2 trial, spearheaded by Dr. Joe Chang. The trial extended over six years, reaffirming the benefit of adding nivolumab to SBRT in yielding better survival rates for recurrent NSCLC cases. The study also revealed insights into blood protein changes that contribute to the effectiveness of this therapy. "Future studies should emphasize biologically informed patient selection," said Chang, noting the potential for integrating AI-driven data for personalized treatment plans. Dr. Joe Chang will present this study on September 27, 2026.
Additionally, new data regarding clonal hematopoiesis of indeterminate potential (CHIP) underscore the significance of monitoring blood cell changes during radiation therapy. Dr. Kevin Nead's research, awarded in the Basic Translational category, identified that CHIP mutations resulting from radiation therapy may detrimentally influence patient outcomes. Nead emphasized that tracking these DNA mutations could guide risk identification and treatment customization. His research findings are also slated for presentation on September 27, 2026.
Collectively, these findings offer promising directions for future research and clinical practice, illustrating the ongoing evolution and refinement of radiation therapies.